118P - Intrapleural hyperthermic chemotherapy (IPHC) may enhance survival in malignant pleural dissemination

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Sook Whan Sung
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors S.W. Sung1, D.S. Noh2, E. Yi2, S.J. Park2, H.C. Yang2, S.C. Cho2, K. Kim2, C. Lim2, S. Jheon2
  • 1Thoarcic And Cardiovascular Surgery, Seoul St. Mary's Hospital, of the Catholic University, 137-701 - Seoul/KR
  • 2Thoracic And Cardiovascular Surgery, SNU Bundang Hospital, Seongnam/KR


Malignant pleural effusion or dissemination of lung cancer is detected in advanced cancer patients, and is generally associated with poor prognosis and poor survival. Palliative chemotherapy and or radiotherapy is not good enough to improve survival. Intrapleural perfusion hyperthermic chemotherapy (IPHC) provides direct effects to cancer tissue. The present study attempted to evaluate the efficacy and safety of IPHC.